RankAlpha logo
Back to Rankings

MIRM

MirumC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
View Chart
Current thesis
The checked evidence supports a constructive post-print read: strong Q1 product sales, a 2026 guide raise, positive recent VISTAS and AZURE-1 milestone language in the earnings update, and a cash position that management says supports operations for at least 12 months [#8-K-2026-05-06] [#10-Q-2026-05-06].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.5.
What can break
Late-2026 pipeline value remains highly dependent on successful AZURE and EXPAND readouts, with normal biotech binary-risk around efficacy, safety, and regulatory interpretation.
Momentum
82
Value
41
Sentiment
43
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $118.00 · Bull $135.00 · Bear $82.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $146.50
Why
Momentum82 · Δ7d -1.5
Value41 · Δ7d +0.0
Sentiment43 · Δ7d -0.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
82
26% active weight
Current posture
7d trendFlat
Δ7d
-1.5
Δ21d
+2.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
43
34% active weight
Current posture
7d trendFlat
Δ7d
-0.7
Δ21d
+2.0
Why this grade

Composite grade C. Momentum 82.4 / Value 41.1 / Sentiment 42.5

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$7.25B
Beta
0.49
Shares Out
60.98M
P/E (TTM) · Derived
-255.4
P/S (TTM)
8.28
P/FCF (TTM)
88.12
Rev YoY
+43.3%
EPS YoY
+4372.5%
Gross Margin
+81.3%
Op Margin
-8.9%
Net Debt
-$63.88M
Current Ratio
2.09
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology